NLTX
Neoleukin Therapeutics
Halal Rating :
Last Price
$16.5
Last updated:
Market Cap
-
7D Change
-12.23 %
1 Year Change
-45.15 %
Company Overview
Industries
Exchange
Next Earnings Date
Nov. 12, 2024
Neoleukin Therapeutics is a biopharmaceutical company focused on creating next generation immunotherapies using de novo protein design technology. The company's lead product candidate, NL-201, is a computationally designed de novo protein that mimics the therapeutic activity of the cytokines IL-2/IL-15 for the treatment of various types of cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $925000.0 | $21.06m | - | $4000.0 | 0.00% | 0.02% |
Company Impact
Help us evaluate Neoleukin Therapeutics's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.